Goldman Sachs
AVTX icon

Goldman Sachs’s Avalo Therapeutics AVTX Stock Holding History

Goldman Sachs’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5M Buy
946,320
+886,214
+1,474% +$14M ﹤0.01% 2772
2026
Q1 		$897K Sell
60,106
-5,207
-8% -$81.4K ﹤0.01% 5169
2025
Q4 		$1.19M Buy
+65,313
New +$1.1M ﹤0.01% 5005
2023
Q2 		– Sell
-134
Closed -$56.5K – 5741
2023
Q1 		$56.5K Sell
134
-4
-3% -$3.15K ﹤0.01% 5533
2022
Q4 		$167K Sell
138
-11
-7% -$14.3K ﹤0.01% 5359
2022
Q3 		$118K Sell
149
-77
-34% -$83.5K ﹤0.01% 5647
2022
Q2 		$324K Buy
226
+44
+24% +$58.9K ﹤0.01% 5375
2022
Q1 		$380K Sell
182
-56
-24% -$141K ﹤0.01% 5512
2021
Q4 		$1.17M Buy
238
+4
+2% +$24K ﹤0.01% 4711
2021
Q3 		$1.47M Buy
234
+76
+48% +$616K ﹤0.01% 4454
2021
Q2 		$1.48M Sell
158
-8
-5% -$67K ﹤0.01% 4461
2021
Q1 		$1.44M Buy
166
+31
+23% +$293K ﹤0.01% 4311
2020
Q4 		$1.03M Buy
135
+79
+141% +$549K ﹤0.01% 4180
2020
Q3 		$369K Buy
56
+5
+10% +$37.6K ﹤0.01% 4629
2020
Q2 		$378K Buy
+51
New +$370K ﹤0.01% 4516
2019
Q2 		– Sell
-15
Closed -$246K – 5116
2019
Q1 		$246K Buy
+15
New +$224K ﹤0.01% 4713
2018
Q4 		– Sell
-6
Closed -$81K – 5226
2018
Q3 		$81K Buy
+6
New +$78.6K ﹤0.01% 5197
2016
Q2 		– Sell
-18
Closed -$194K – 7014
2016
Q1 		$194K Buy
+18
New +$178K ﹤0.01% 5652

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Goldman Sachs's AVTX Position: Q2 2026 in Review

Goldman Sachs increased its Avalo Therapeutics (AVTX) stake by 1,474% in Q2 2026, buying an estimated $14M and bringing the position to 946,320 shares worth $17.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2772.

Goldman Sachs first reported a position in AVTX in Q1 2016 and has held it in 18 quarters since. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Goldman Sachs held 946,320 shares of Avalo Therapeutics worth $17.5M as of Q2 2026.
  • Goldman Sachs bought 886,214 Avalo Therapeutics shares in Q2 2026, an estimated $14M.
  • Avalo Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2772 holding.
  • Goldman Sachs first reported a position in Avalo Therapeutics in Q1 2016 and has held it in 18 quarters since.
  • 125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.